Bone Metastases: From Mechanisms to Treatment.
Bone metastasis
Cancer
Individual treatment
Mechanisms
Osteolytic
Sclerotic
Journal
Seminars in oncology nursing
ISSN: 1878-3449
Titre abrégé: Semin Oncol Nurs
Pays: United States
ID NLM: 8504688
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
pubmed:
28
4
2022
medline:
26
5
2022
entrez:
27
4
2022
Statut:
ppublish
Résumé
Bone metastases are of high clinical relevance because they are a frequent complication of most types of common cancers, such as breast and prostate. The metastatic process is complex, requiring the completion of several different steps to allow successful dissemination and homing. In addition, preparation of the metastatic niche changes the constant cycle of bone matrix formation and degradation, leading to the clinical phenotypes of lytic and sclerotic lesions. We review our current knowledge on this topic and briefly explain the current treatment landscape of bone metastasis. These include PubMed, international guidelines, and clinician experience. Bone metastases remain a clinical challenge that negatively impacts patients prognosis and quality of life. A comprehensive understanding of the complex molecular mechanisms that results in bone metastasis is the basis for successful treatment of affected patients. The disruption of bone matrix metabolism is already recognized as the prerequisite for metastasis formation, but many open questions remain that need to be addressed in future research to establish individually tailored treatment approaches. Patient-centered therapy of bone metastases requires suitable pharmacological options, and importantly a holistic approach in care delivery across the multidisciplinary team. Nurses provide the cornerstone of the multidisciplinary team and provide the closest and the most frequent contact to the patient and their families to provide timely intervention. Nurses require a basic understanding of the complex physiology of metastasis to inform practice.
Identifiants
pubmed: 35474145
pii: S0749-2081(22)00030-4
doi: 10.1016/j.soncn.2022.151277
pii:
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
151277Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors have received grants or honorarium for advisory boards or lectures to the individual or the institution by Amgen (TDR), Biomedica (AG), RMR has no conflicts of interest.